Literature DB >> 26637687

The prognostic and therapeutic factors which influence the oncological outcome of parosteal osteosarcoma.

M Laitinen1, M Parry2, J I Albergo3, L Jeys2, A Abudu2, S Carter2, V Sumathi2, R Grimer2.   

Abstract

The aim of this study was to evaluate the prognostic and therapeutic factors which influence the oncological outcome of parosteal osteosarcoma. A total of 80 patients with a primary parosteal osteosarcoma were included in this retrospective study. There were 51 females and 29 males with a mean age of 29.9 years (11 to 78). The mean follow-up was 11.2 years (1 to 40). Overall survival was 91.8% at five years and 87.8% at ten years. Local recurrence occurred in 14 (17.5%) patients and was associated with intralesional surgery and a large volume of tumour. On histological examination, 80% of the local recurrences were dedifferentiated high-grade tumours. A total of 12 (14.8%) patients developed pulmonary metastases, of whom half had either a dedifferentiated tumour or a local recurrence. Female gender and young age were good prognostic factors. Local recurrence was a poor prognostic factor for survival. Medullary involvement or the use of chemotherapy had no impact on survival. The main goal in treating a parosteal osteosarcoma must be to achieve a wide surgical margin, as inadequate margins are associated with local recurrence. Local recurrence has a significant negative effect on survival, as 80% of the local recurrences are high-grade dedifferentiated tumours, and half of these patients develop metastases. The role of chemotherapy in the treatment of parosteal osteosarcoma is not as obvious as it is in the treatment of conventional osteosarcoma. The mainstay of treatment is wide local excision. ©2015 The British Editorial Society of Bone & Joint Surgery.

Entities:  

Keywords:  Parosteal osteosarcoma; local recurrence; metastases; survival

Mesh:

Year:  2015        PMID: 26637687     DOI: 10.1302/0301-620X.97B12.35749

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  6 in total

1.  Are Skin Fiducials Comparable to Bone Fiducials for Registration When Planning Navigation-assisted Musculoskeletal Tumor Resections in a Cadaveric Simulated Tumor Model?

Authors:  Rodolfo Zamora; Stephanie E Punt; Claudia Christman-Skieller; Cengiz Yildirim; John C Shapton; Ernest U Conrad
Journal:  Clin Orthop Relat Res       Date:  2019-12       Impact factor: 4.176

Review 2.  A review of imaging of surface sarcomas of bone.

Authors:  Kelly Harper; Paul Sathiadoss; Asif Saifuddin; Adnan Sheikh
Journal:  Skeletal Radiol       Date:  2020-07-17       Impact factor: 2.199

3.  Oncological and Functional Outcomes after Hemicortical Resection and Biological Reconstruction Using Allograft for Parosteal Osteosarcoma of the Distal Femur.

Authors:  Olga D Savvidou; Stavros Goumenos; Ioannis Trikoupis; Angelos Kaspiris; Dimitra Melissaridou; Panagiotis Gavriil; Jimmy Georgoulis; Panayiotis J Papagelopoulos
Journal:  Sarcoma       Date:  2022-06-02

4.  Long-Term Functional Outcomes of Distal Femoral Replacements Compared to Geographic Resections for Parosteal Osteosarcomas of the Distal Femur.

Authors:  Benjamin K Wilke; Anna R Cooper; C Parker Gibbs; Mark T Scarborough; Andre R Spiguel
Journal:  Iowa Orthop J       Date:  2018

Review 5.  Advances in the management of osteosarcoma.

Authors:  Stefan S Bielack; Stefanie Hecker-Nolting; Claudia Blattmann; Leo Kager
Journal:  F1000Res       Date:  2016-11-25

6.  Parosteal Osteosarcoma with Pancreatic Metastasis and Multiple Relapses: A Case Report and Review of the Literature.

Authors:  Daniel Cirotski; Jyoti Panicker
Journal:  Case Rep Oncol       Date:  2021-06-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.